The Technical Field "アミノ酸配列" had 105 patent application filings in the most recent period (2023-01-01 to 2023-04-30). This is a significantly decreased of -758 filings (-87.8%) over 863 they had in the same period of the previous year (2022-01-01 to 2022-04-30). This report also includes technical terms related to " アミノ酸シーケンス ", " ペプチド配列 " in the search set.
The highest number of filings in 2019 with 3,276 cases, and their lowest number in 2023 with 179 cases.
The mean of the number of filings over the last 5 years (2019 to 2024, 11,503 cases in total) is 1,917, and the median is 2,580. The coefficient of variation (standard deviation/mean) is 0.7, and there have been relatively large fluctuations in the number of filings from year to year.
Index | Value |
---|---|
Average | 1,917 patents |
Std Dev | 1,306 |
COV | 0.7 |
Year | Cases | YOY |
---|---|---|
2023 year | 179 cases | -92.7 % |
2022 year | 2,439 cases | -14.69 % |
2021 year | 2,859 cases | +5.11 % |
This report provides the latest patent analysis information (the IP landscape, including a patent map) on the patent search results of the JP patent database for アミノ酸配列 for the period of the last 10 years (2015-01-01 to 2024-12-31). You can compare the information in this report with the trends in your competitors’ patent filings and technologies, and use it to search for important patents.
This service provides, free of charge, a patent analysis report based on the latest patent data (Japanese, U.S., European, and PCT application publications) for use in patent searches, patent analysis, and IP landscaping. The service is offered by "Patent Integration" a firm specializing in patent search/patent analysis.
This report includes basic information to help you understand the IP strategy and management of アミノ酸配列, such as changes in the number of patents/patent applications they have filed, comparisons of the numbers of patents/patent applications filed by their peers and competitors, their top coapplicants (joint research partners, alliance partners), and their most important patents. It can be used in various intellectual property business operations such as IP landscaping, patent search/patent analysis, preparation of intellectual property business evaluation reports, selection of M&A candidates, and selection of alliance partners.
He is a patent attorney at a patent office. He specializes in invention counseling, patent filing, and intellectual property strategies for start-up companies and new businesses in the fields of software, information technology and artificial intelligence. He runs a patent course for beginners on Udemy, an online course provider.
After studying physics at the University of Tokyo as a doctoral student, he was engaged in intellectual property analysis and technology trend research as an in-house patent attorney at a precision equipment manufacturer and at Toyota Central R&D Labs. Inc..
The concept of the "IP landscape" (IPL) has been attracting attention recently.
An IP landscape is not limited to patent information, but also integrates and analyzes business information (e.g., non-patent information such as papers, news releases, stock information, and market information). Intellectual-property-based business management is realized through the analysis of intellectual property information applied to the formulation of management strategies and business strategies. This is a comprehensive approach that includes but not limited to planning of open and closed strategies, selecting M&A candidates, searching for alliance partners, and formulating intellectual property strategies, through the exploitation of intellectual property information.
IP landscaping usually includes patent search and patent analysis. In patent search and patent analysis, it is important to grasp the market position of each company and the overall technological trends and development trends for each technology. More specifically, it is important to understand what intellectual property your own company and other companies hold, what the strengths and weaknesses of other companies are, and how other companies are trying to exploit their intellectual property. In other words, it is important to understand both the business strategy and the intellectual property strategy of each company.
After reading this search report, you may be interested in more detailed patent searches and patent analysis. We offer a service called Patent Integration, which is an integrated patent search and patent analysis service. With reasonable pricing and a simple user interface such that even beginners can quickly search for and analyze patent information by company or technology from a web browser, please consider using it for detailed patent searches, patent analysis, and IP landscaping.
Patent Integration has a patent-landscaping function that can visually represent a set of tens of thousands of patents/patent applications. This allows you to convincingly show the technical positions of your company and its competitors to your management and business strategists in order to formulate management strategies and business strategies.
The changes in the number of patent filings of アミノ酸配列 over the last 20 years (JP) are shown below.
The change in the number of patents/patent applications is the most basic index in patent analysis. By examining the change in the number of patents/patent applications, you can see the status of technological development and R&D focus for each company or technology. It should be noted that since there is a one and a half year lag between the filing and the laying open of patent applications, it is not possible to analyze the situation more recently than one and half years prior to the present.
In this report, you can only see the change in the number of patents/patent applications by company or technology, whereas Patent Integration allows you to quickly compare the number of patent applications with your competitors in each technical field by cross-referencing with other keywords and patent classifications.
This patent analysis report was created for a patent search set of 23,675 cases retrieved by applying the following search formula and analysis period to the following patent database. Patent information such as a patent analysis result, a patent map, and a patent landscape can be freely used for patent searches, analysis, and work on intellectual property strategies, including IP landscaping.
The number of patents and changes in the number of patents of other companies (competitors) in the same industry as アミノ酸配列 are shown below.
Comparison of changes in the number of patents with peers and competitors is an important analytical index for understanding the intellectual property strategies of each company. By checking the transition of the number of patents for each company / competitor, you can check the status of focus on technology development and R&D for each company / technology.
It should be noted that patents have a time lag of one and a half years from filing to publication, so it is not possible to analyze the situation more recent than one and a half years.
If you want to find out more information, " Patent Integration , You can compare the number of patent applications with competitors in each technical field in a short time by multiplying with other keywords and patent classifications.Please use it for more detailed patent information analysis such as selection of M&A candidate destinations and alliance destinations.
Comparing the number of applications of each company, 国立研究開発法人産業技術総合研究所 has the highest number of joint applications in the last in the last 3 years (2023 to 2025) with 6 cases, followed by 味の素株式会社 with 4 cases.
Name | Cases |
---|---|
国立研究開発法人産業技術総合研究所 | 6 cases |
味の素株式会社 | 4 cases |
中外製薬株式会社 | 3 cases |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 1 cases |
エフホフマン-ラロシュアーゲー | 1 cases |
Comparing the number of applications of each company, ジェネンテックインコーポレイテッド has the highest number of joint applications in the last for the target period (2015 to 2025) with 398 cases, followed by リジェネロン・ファーマシューティカルズ・インコーポレイテッド with 398 cases.
Name | Cases |
---|---|
ジェネンテックインコーポレイテッド | 398 cases |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 398 cases |
ノバルティスアーゲー | 284 cases |
エフホフマン-ラロシュアーゲー | 189 cases |
中外製薬株式会社 | 170 cases |
アムジエン・インコーポレーテツド | 157 cases |
味の素株式会社 | 125 cases |
国立研究開発法人産業技術総合研究所 | 113 cases |
武田薬品工業株式会社 | 72 cases |
国立研究開発法人科学技術振興機構 | 11 cases |
ヒューマンジノームサイエンシーズインコーポレイテッド | 1 cases |
Below is a patent map showing changes in the number of applications for JP patents of 11 companies in the same industry over the past 20 years.
The number of patents and changes in the number of patents of other companies (competitors) in the same industry as アミノ酸配列 are shown below.
Comparison of changes in the number of patents with peers and competitors is an important analytical index for understanding the intellectual property strategies of each company. By checking the transition of the number of patents for each company / competitor, you can check the status of focus on technology development and R&D for each company / technology.
It should be noted that patents have a time lag of one and a half years from filing to publication, so it is not possible to analyze the situation more recent than one and a half years.
If you want to find out more information, " Patent Integration , You can compare the number of patent applications with competitors in each technical field in a short time by multiplying with other keywords and patent classifications.Please use it for more detailed patent information analysis such as selection of M&A candidate destinations and alliance destinations.
Among the top coapplicants, 国立研究開発法人産業技術総合研究所 has the highest number of joint applications in the last in the last 3 years (2023 to 2025) with 6 cases, followed by 味の素株式会社 with 4 cases.
Name | Cases |
---|---|
国立研究開発法人産業技術総合研究所 | 6 cases |
味の素株式会社 | 4 cases |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 1 cases |
Among the top coapplicants, ジェネンテックインコーポレイテッド has the highest number of joint applications in the last for the target period (2015 to 2025) with 398 cases, followed by リジェネロン・ファーマシューティカルズ・インコーポレイテッド with 398 cases.
Name | Cases |
---|---|
ジェネンテックインコーポレイテッド | 398 cases |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 398 cases |
ノバルティスアーゲー | 284 cases |
味の素株式会社 | 125 cases |
国立研究開発法人産業技術総合研究所 | 113 cases |
武田薬品工業株式会社 | 72 cases |
国立研究開発法人科学技術振興機構 | 11 cases |
Below is a ranking of the number of JP patent applications by アミノ酸配列’s top 7 coapplicants over the last 20 years.
Below is a patent map showing the changes in the numbers of JP patent filings by アミノ酸配列’s top 7 coapplicants over the last 20 years.
アミノ酸配列 filed 398 joint applications with ジェネンテックインコーポレイテッド for the analysis period (2015 to 2025).
The mean of the number of filings over the last 5 years (2019 to 2024, 119 cases in total) is 19.8, and the median is 25.5. The coefficient of variation (standard deviation/mean) is 0.7, and there have been relatively large fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2021 to 2024). The highest number of filings in 2015 with 95 cases, and their lowest number in 2023 with 0 cases.
Index | Value |
---|---|
Average | 19.8 patents |
Std Dev | 14.5 |
COV | 0.7 |
Year | Cases | YOY |
---|---|---|
2022 year | 27 cases | -15.62 % |
2021 year | 32 cases | +33.3 % |
2020 year | 24 cases | -33.3 % |
アミノ酸配列 filed 72 joint applications with 武田薬品工業株式会社 for the analysis period (2015 to 2025).
The mean of the number of filings over the last 5 years (2019 to 2024, 35 cases in total) is 5.8, and the median is 6.0. The coefficient of variation (standard deviation/mean) is 0.8, and there have been relatively large fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2021 to 2024). The highest number of filings in 2017 with 14 cases, and their lowest number in 2023 with 0 cases.
Index | Value |
---|---|
Average | 5.8 patents |
Std Dev | 4.8 |
COV | 0.8 |
Year | Cases | YOY |
---|---|---|
2022 year | 4 cases | -66.7 % |
2021 year | 12 cases | +50.0 % |
2020 year | 8 cases | -27.27 % |
アミノ酸配列 filed 113 joint applications with 国立研究開発法人産業技術総合研究所 for the analysis period (2015 to 2025).
The mean of the number of filings over the last 5 years (2019 to 2024, 47 cases in total) is 7.8, and the median is 9.0. The coefficient of variation (standard deviation/mean) is 0.5, and there have been big fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2021 to 2024). The highest number of filings in 2017 with 19 cases, and their lowest number in 2023 with 5 cases.
Index | Value |
---|---|
Average | 7.8 patents |
Std Dev | 3.8 |
COV | 0.5 |
Year | Cases | YOY |
---|---|---|
2023 year | 5 cases | -50.0 % |
2022 year | 10 cases | +11.11 % |
2021 year | 9 cases | 0 |
アミノ酸配列 filed 11 joint applications with 国立研究開発法人科学技術振興機構 for the analysis period (2015 to 2025).
The mean of the number of filings over the last 5 years (2019 to 2024, 4 cases in total) is 0.7, and the median is 0.5. The coefficient of variation (standard deviation/mean) is 1.1, and there have been very big fluctuations in the number of filings from year to year.
The highest number of filings in 2015 with 6 cases, and their lowest number in 2023 with 0 cases.
Index | Value |
---|---|
Average | 0.7 patents |
Std Dev | 0.7 |
COV | 1.1 |
Year | Cases | YOY |
---|---|---|
2022 year | 1 cases | - |
2021 year | 0 cases | -100 % |
2020 year | 1 cases | -50.0 % |
アミノ酸配列 filed 284 joint applications with ノバルティスアーゲー for the analysis period (2015 to 2025).
The mean of the number of filings over the last 5 years (2019 to 2024, 85 cases in total) is 14.2, and the median is 13.0. The coefficient of variation (standard deviation/mean) is 0.9, and there have been relatively large fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2021 to 2024). The highest number of filings in 2015 with 63 cases, and their lowest number in 2023 with 0 cases.
Index | Value |
---|---|
Average | 14.2 patents |
Std Dev | 12.6 |
COV | 0.9 |
Year | Cases | YOY |
---|---|---|
2022 year | 9 cases | -47.1 % |
2021 year | 17 cases | -32.0 % |
2020 year | 25 cases | -26.47 % |
The following shows JP patents held by アミノ酸配列 that have had an invalidation trial against them demanded or an opposition filed against them by a third party, and アミノ酸配列’s JP patents/patent applications of high importance cited by Examiners in patent examination processes.
By noting the most important patents, you can obtain knowledge of the competitive business environment in which アミノ酸配列 is placed (e.g., whether it is a fiercely competitive environment or an oligopolistic market and the like). In general, it can be understood that a company with a large number of demands for invalidation trials is developing their business in a business environment where IP disputes are common.
If you want to search for more detailed information, you can use Patent Integration to retrieve and download by company cited patents/patent applications or patents undergoing invalidation trials. You can quickly extract important patents from a patent set that includes multiple competitors by cross-referencing with other keywords and patent classifications. Please consider using it for searches for important patents/patent applications.
In the last 3 years (2022-01-01 ~ 2024-12-31), there were 5 patents Invalidation Trial from third parties. The average number of Invalidation Trial is 1.0 times. The most recently Invalidation Trial patent is 特許7016341 "PD-1軸結合アンタゴニスト及びTIGIT阻害剤を使用するがんの治療方法" (Invalidation Trial day 2023-03-27) , next is 特許6896700 "ワクチン組成物" (Invalidation Trial day 2023-01-27) .
- | No. | Title | Invalidation Trial days |
---|---|---|---|
1 | 特許7016341 | PD-1軸結合アンタゴニスト及びTIGIT阻害剤を使用するがんの治療方法 | 2023-03-27 |
2 | 特許6896700 | ワクチン組成物 | 2023-01-27 |
3 | 特許6278598 | 細胞傷害誘導治療剤 | 2022-03-31 |
4 | 特許6773929 | 細胞傷害誘導治療剤 | 2022-03-31 |
5 | 特許6692856 | RNA依存性標的DNA修飾およびRNA依存性転写調節のための方法および組成物 | 2022-02-25 |
Of the patent applications filed in the last 10 years (2015-01-01 to 2024-12-31), 5 patents/patent applications were invalidation trial more than once in the examination process of other patent applications. The mean of the number of invalidation trial is 1.2. The most invalidation trial patent is 特許5906333 "プロタンパク質コンベルターゼスブチリシンケクシン9型(PCSK9)に対する抗原結合タンパク質" (2 times) , and the next most invalidation trial patent is 特許6522072 "イズロン酸−2−スルファターゼのCNS送達のための方法および組成物" (1 times) .
- | No. | Title | |
---|---|---|---|
1 | 特許5906333 | プロタンパク質コンベルターゼスブチリシンケクシン9型(PCSK9)に対する抗原結合タンパク質 | 2 times |
2 | 特許6522072 | イズロン酸−2−スルファターゼのCNS送達のための方法および組成物 | 1 times |
3 | 特許6896700 | ワクチン組成物 | 1 times |
4 | 特許6074462 | 抗−TNFα抗体の投与方法 | 1 times |
5 | 特許6302529 | 抗−TNFα抗体の投与方法 | 1 times |
In the last 3 years (2022-01-01 ~ 2024-12-31), there were 17 patents Opposition from third parties. The average number of Opposition is 1.0 times. The most recently Opposition patent is 特許7438604 "SARS-COV-2 mRNAドメインワクチン" (Opposition day 2024-08-23) , next is 特許7420330 "アレルギーの抗原およびそのエピトープ" (Opposition day 2024-07-10) .
- | No. | Title | Opposition days |
---|---|---|---|
1 | 特許7438604 | SARS-COV-2 mRNAドメインワクチン | 2024-08-23 |
2 | 特許7420330 | アレルギーの抗原およびそのエピトープ | 2024-07-10 |
3 | 特許7405964 | アミラーゼを含む自動食器洗浄用洗剤組成物 | 2024-05-13 |
4 | 特許7448953 | 眼疾患のための細胞モデル及び治療関連出願への相互参照 | 2024-04-17 |
5 | 特許7328390 | フィブロイン様タンパク質の製造法 | 2024-02-15 |
6 | 特許7270912 | アドレノメデュリン濃度変動による予後予測の情報提供方法及びその試薬 | 2023-11-13 |
7 | 特許7240675 | オトフェルリンを発現させるための組成物および方法 | 2023-09-19 |
8 | 特許7232758 | 膜透過性の高い環状ペプチド化合物、及びこれを含むライブラリ | 2023-09-05 |
9 | 特許7222347 | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 | 2023-08-11 |
10 | 特許7179776 | 孵化していない卵における鳥類胚の性決定方法およびその手段 | 2023-05-24 |
In the last 3 years (2022-01-01 ~ 2024-12-31), there were 38 patents Protest from third parties. The average number of Protest is 1.2 times. The most recently Protest patent is 特開2021-132601 "油脂酵母の油脂生産制御因子" (Protest day 2024-12-23) , next is 特開2023-032890 "細胞質雄性不稔性遺伝子、雄性不稔回復植物、ナス科植物の細胞質雄性不稔の稔性を回復する方法、雄性不稔回復植物の製造方法、雄性不稔性植物、及び雄性不稔性植物の製造方法" (Protest day 2024-11-29) .
- | No. | Title | Protest days |
---|---|---|---|
1 | 特開2021-132601 | 油脂酵母の油脂生産制御因子 | 2024-12-23 |
2 | 特開2023-032890 | 細胞質雄性不稔性遺伝子、雄性不稔回復植物、ナス科植物の細胞質雄性不稔の稔性を回復する方法、雄性不稔回復植物の製造方法、雄性不稔性植物、及び雄性不稔性植物の製造方法 | 2024-11-29 |
3 | 特開2023-052910 | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 | 2024-11-28 |
4 | 特開2023-153942 | フィブロイン様タンパク質の製造法 | 2024-11-01 |
5 | 特表2022-521426 | 安定なタンパク質製剤 | 2024-09-17 |
6 | 特表2022-546587 | 生物製剤の捕捉及び精製のための方法 | 2024-08-22 |
7 | 再公表2019/240288 | 抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩 | 2024-08-08 |
8 | 特表2023-517644 | コロナウイルスワクチン組成物及び方法 | 2024-06-15 |
9 | 特開2021-116244 | 高純度プロタミン硫酸塩 | 2024-05-29 |
10 | 特開2023-171429 | 新規リパーゼ及びその用途 | 2024-02-21 |
11 | 特開2023-052694 | 悪臭調節化合物の同定方法 | 2024-02-17 |
12 | 特開2022-187349 | 含硫化合物臭の抑制剤の探索方法 | 2024-02-17 |
13 | 特開2023-174085 | アンモニア臭の抑制剤の探索方法 | 2024-02-17 |
14 | 特表2022-548197 | 抗VEGFタンパク質組成物及びその製造方法 | 2024-01-15 |
15 | 特許7532752 | 改良されたウイルス検出方法 | 2023-11-06 |
16 | 特許7516731 | 改良されたウイルス検出方法 | 2023-11-06 |
17 | 特許7438604 | SARS-COV-2 mRNAドメインワクチン | 2023-10-27 |
18 | 特許7573523 | 工業的規模でテレフタル酸を製造するための方法 | 2023-08-30 |
19 | 特表2021-503278 | CasZ組成物及び使用方法 | 2023-07-06 |
20 | 特開2023-036582 | がんのための治療方法及び診断方法 | 2023-06-26 |
Of the patent applications filed in the last 10 years (2015-01-01 to 2024-12-31), 80 patents/patent applications were protest more than once in the examination process of other patent applications. The mean of the number of protest is 1.3. The most protest patent is 特開2017-061467 "血管新生眼疾患を処置するためのVEGFアンタゴニストの使用" (5 times) , and the next most protest patent is 特許6616332 "マイコプラズマ・ニューモニエの免疫学的検出法及びキット" (5 times) .
- | No. | Title | |
---|---|---|---|
1 | 特開2017-061467 | 血管新生眼疾患を処置するためのVEGFアンタゴニストの使用 | 5 times |
2 | 特許6616332 | マイコプラズマ・ニューモニエの免疫学的検出法及びキット | 5 times |
3 | 特許6616333 | マイコプラズマ・ニューモニエの免疫学的検出法およびキット | 4 times |
4 | 再公表2019/240288 | 抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩 | 4 times |
5 | 特許7117824 | モノクローナル抗体、検出方法、及び検出装置 | 3 times |
In the last 3 years (2022-01-01 ~ 2024-12-31), there were 365 patents Inspection from third parties. The average number of Inspection is 1.2 times. The most recently Inspection patent is 特表2023-510211 "抗NKp30抗体及び使用方法" (Inspection day 2024-12-27) , next is 特表2024-510142 "甲状腺眼症の処置のための方法" (Inspection day 2024-12-26) .
- | No. | Title | Inspection days |
---|---|---|---|
1 | 特表2023-510211 | 抗NKp30抗体及び使用方法 | 2024-12-27 |
2 | 特表2024-510142 | 甲状腺眼症の処置のための方法 | 2024-12-26 |
3 | 特表2021-503278 | CasZ組成物及び使用方法 | 2024-12-24 |
4 | 特表2021-534220 | 抗HER2ポリペプチド及びそれらの使用の方法 | 2024-12-24 |
5 | 特表2022-517952 | 分子エレクトロニクスのための伝導性合成ペプチド | 2024-12-18 |
6 | 特表2022-539388 | CCL14の抗体およびアッセイ | 2024-12-13 |
7 | 特開2023-052910 | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 | 2024-12-12 |
8 | 特表2023-509263 | アフリベルセプトをコードするAAV2バリアントを使用する眼内血管新生疾患を処置する方法 | 2024-12-10 |
9 | 特開2023-062063 | 抗KIT抗体及びその使用 | 2024-12-10 |
10 | 特表2021-519758 | LFA3バリアントならびにその組成物および使用法 | 2024-12-06 |
11 | 特表2021-525549 | 腫瘍特異的ネオ抗原およびその使用方法 | 2024-12-04 |
12 | 特許7607590 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト | 2024-12-03 |
13 | 特開2023-153942 | フィブロイン様タンパク質の製造法 | 2024-11-27 |
14 | 特表2022-547154 | 調節可能な制御のためのCA2-IL15融合タンパク質 | 2024-11-25 |
15 | 特許6231007 | BCMAおよびCD3に対する結合分子 | 2024-11-15 |
16 | 特許7250736 | BCMAおよびCD3に対する結合分子 | 2024-11-15 |
17 | 特許7194240 | 抗BCMA抗体、BCMA及びCD3に結合する二重特異性抗原結合分子、並びにそれらの使用 | 2024-11-15 |
18 | 特許6378087 | BCMAおよびCD3に対する結合分子 | 2024-11-15 |
19 | 特開2017-195889 | BCMAおよびCD3に対する結合分子 | 2024-11-15 |
20 | 特開2023-027228 | 抗BCMA抗体、BCMA及びCD3に結合する二重特異性抗原結合分子、並びにそれらの使用 | 2024-11-15 |
Of the patent applications filed in the last 10 years (2015-01-01 to 2024-12-31), 648 patents/patent applications were inspection more than once in the examination process of other patent applications. The mean of the number of inspection is 1.2. The most inspection patent is 特許6616332 "マイコプラズマ・ニューモニエの免疫学的検出法及びキット" (9 times) , and the next most inspection patent is 特許6616333 "マイコプラズマ・ニューモニエの免疫学的検出法およびキット" (9 times) .
- | No. | Title | |
---|---|---|---|
1 | 特許6616332 | マイコプラズマ・ニューモニエの免疫学的検出法及びキット | 9 times |
2 | 特許6616333 | マイコプラズマ・ニューモニエの免疫学的検出法およびキット | 9 times |
3 | 特許7117824 | モノクローナル抗体、検出方法、及び検出装置 | 8 times |
4 | 特開2017-061467 | 血管新生眼疾患を処置するためのVEGFアンタゴニストの使用 | 8 times |
5 | 再公表2019/240288 | 抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩 | 7 times |
Of the patent applications filed in the last 10 years (2015-01-01 to 2024-12-31), 3,083 patents/patent applications were cited more than once in the examination process of other patent applications. The mean of the number of cited is 2.2. The most cited patent is 特許6196343 "免疫グロブリンに特異的に結合するタンパク質および免疫グロブリン結合性アフィニティーリガンド" (36 times) , and the next most cited patent is 特許6352974 "ワクチンのための高力価組み換えインフルエンザ・ウィルス" (28 times) .
- | No. | Title | |
---|---|---|---|
1 | 特許6196343 | 免疫グロブリンに特異的に結合するタンパク質および免疫グロブリン結合性アフィニティーリガンド | 36 times |
2 | 特許6352974 | ワクチンのための高力価組み換えインフルエンザ・ウィルス | 28 times |
3 | 特許6842926 | IL−15ベース分子及びその使用方法 | 25 times |
4 | 特許6375329 | ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス | 25 times |
5 | 特許6731346 | 標的TGFβ阻害 | 24 times |
"Patent Integration Report" is a web service provided by "Patent Integration Co., Ltd." operated by patent attorneys who are experts in intellectual property rights. Based on the latest patent data, this is one of the largest patent report services in Japan that provides information on technology trends in various companies and technology fields.
The purpose of this web service is to make intellectual property information familiar to many people, regardless of whether they have an interest in intellectual property rights, and to make use of it.
We actively provide various types of patent information that can be used in various media articles such as newspapers, magazines, and web media. Please feel free to contact us from "Inquiry form for details on the content of patent information that can be provided, conditions for provision, etc. Please contact us.
All rights related to the data, documents and charts belong to "an integrated patent search/analysis service provider, Patent Integration". Please specify the source “Patent Integration Report, URL: https://patent-i.com/report/en/" when inserting them into in-house materials, external report materials, etc., regardless of whether they are paid or free of charge.
Patent data is obtained by aggregating and analyzing the latest patent data issued by the Patent Offices of respective countries and jurisdictions and by WIPO. Although we take great care in publishing and analyzing the results, we do not guarantee the correctness of the data. We appreciate your understanding.
If you have any concerns about this service, please feel free to contact us.
All rights to the data, documents, figures and tables are reserved by e-Patent. When publishing internal documents, external reports, etc. (whether paid or free of charge), please use the following URL: https://e-patent.co.jp/.
e-Patent will not be liable for any damages or losses arising from the use of the global patent application status, ranking information, or population search formula in the "SDGs Global Company Ranking from a Patent Perspective". Items with ● in front of the target are not supported at this time (judged to be difficult to approach from the patent information analysis).
There is no problem to cite patent application status and ranking information, but please clearly indicate "Source: e-Patent Co.
Credit notation
・MeCab user dictionary for science technology term © National Bioscience Database Center licensed under CC Attribution-Share Alike 4.0 International